Back to top

immuno-therapy: Archive

Sanghamitra Saha

Is Healthcare Losing the Status of Safe Haven? ETFs in Focus

Healthcare stocks face new risks under Trump, despite their usual defensive reputation.

PFEPositive Net Change SPYNegative Net Change XLVPositive Net Change XHSNegative Net Change IHEPositive Net Change MEDPPositive Net Change IDNAPositive Net Change

Zacks Equity Research

AstraZeneca's Imfinzi Gets FDA Nod for Bladder Cancer Indication

The FDA approves AZN's sBLA seeking the expanded use of Imfinzi for adult patients with muscle-invasive bladder cancer.

AZNPositive Net Change DVAXPositive Net Change BAYRYNegative Net Change CORTNegative Net Change

Zacks Equity Research

AZN to Acquire EsoBiotec for $1B to Develop In Vivo Cell Therapies

AstraZeneca is set to acquire EsoBiotec for $1 billion to develop in vivo cell therapies for multiple cancer indications or immune-mediated diseases.

AZNPositive Net Change BMRNPositive Net Change GILDPositive Net Change CORTNegative Net Change

Bryan Hayes

Follow the Leader: 2 Biopharma Stocks Showing Relative Strength in 2025

Despite a correction to begin the year, there are a few pockets of the market that are working.

GILDPositive Net Change JAZZPositive Net Change

Bryan Hayes

Pharmaceutical Stocks Hit New Highs Amid Market Volatility

During this time of heightened market volatility, it pays to be invested in the right places.

GILDPositive Net Change